Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 13,066 matching trials from the live ClinicalTrials.gov search.

Filters: Atlanta, Georgia Clear all

Conditions: Necrotizing Fascitis
Interventions: Administration of indocyanine green (ICG) and fluorescence imaging; Diagnostic Test
Lead sponsor: Eric R. Henderson; Other
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Los Angeles, California • Stanford, California • Atlanta, Georgia + 5 more

Conditions: Lymphoma
Interventions: rituximab, cyclophosphamide, doxorubicin, prednisone, vincristine, tositumomab; Biological · Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2025
U.S. locations: 259
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 167 more

Conditions: Colorectal Cancer, Neoplasms, Colorectal
Interventions: CS7017, irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI); Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Beverly Hills, California • Fullerton, California • Washington D.C., District of Columbia + 3 more

Conditions: Central Nervous System Infection
Interventions: Delve Detect CSF mNGS Test, Real-World Data; Diagnostic Test · Other
Lead sponsor: Delve Bio, Inc.; Industry
Eligibility: Not listed
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 3 more

Conditions: Social Anxiety Disorder
Interventions: Virtual Reality Exposure Therapy, Exposure Group Therapy; Behavioral
Lead sponsor: Georgia State University; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Granulomatous Disease (CGD)
Interventions: Not listed
Lead sponsor: Ensoma; Industry
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 50
States / cities: Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more

Conditions: Substance Use Disorders
Interventions: Peer recovery coaching with linkage to recovery resources, Usual Care; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Advanced MDS, Acute Myeloid Leukemia
Interventions: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 17 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Atlanta, Georgia • Houston, Texas

Conditions: Schizophrenia
Interventions: ALKS 9072, Low Dose, ALKS 9072, High Dose; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 17
States / cities: Little Rock, Arkansas • Garden Grove, California • Oakland, California + 11 more

Conditions: Lumbosacral Radiculopathy
Interventions: z160, Placebo; Drug
Lead sponsor: Zalicus; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 23
States / cities: Huntsville, Alabama • Peoria, Arizona • Anaheim, California + 19 more

Conditions: Heart Failure, Congestive
Interventions: Cardiac Resynchronization Therapy Device; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 1,024 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 93
States / cities: Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 90 more

Conditions: Ulcerative Colitis
Interventions: Melatonin, Placebo; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 69 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
Interventions: MEDI4736, Tremelimumab, MEDI4736 + Tremelimumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 96 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 43
States / cities: Birmingham, Alabama • Yuma, Arizona • Little Rock, Arkansas + 38 more

Conditions: Posttraumatic Stress Disorder
Interventions: Mindfulness Based Stress Reduction, Present Centered Group Therapy; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Tuscaloosa, Alabama • Decatur, Georgia • Charleston, South Carolina

Conditions: Phenylketonuria
Interventions: JNT-517 Suspension, Placebo Suspension, JNT-517 Tablet, Placebo Tablet; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 11
States / cities: Gainesville, Florida • Tampa, Florida • Atlanta, Georgia + 8 more

Conditions: Lyme Disease
Interventions: mRNA-1975, mRNA-1982, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 807 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 20
States / cities: Milford, Connecticut • Stamford, Connecticut • Waterbury, Connecticut + 17 more

Conditions: Tuberculosis
Interventions: RPT + INH once weekly for 3 months given by DOT, Isoniazid (INH) daily for 9 months; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 2 Years and older
Enrollment: 8,053 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2013
U.S. locations: 21
States / cities: Little Rock, Arkansas • Los Angeles, California • San Diego, California + 17 more

Conditions: HIV-1 Infection
Interventions: DOR/ISL, BIC/FTC/TAF, Placebo to DOR/ISL, Placebo to BIC/FTC/TAF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 38
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 29 more

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Prompt Sham, Prompt aflibercept, Deferred laser, Deferred aflibercept; Procedure · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 81
States / cities: Phoenix, Arizona • Tucson, Arizona • Huntington Beach, California + 68 more

Conditions: Perioperative Complication
Interventions: Exercise Group, Nutrition Group; Behavioral · Dietary Supplement
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Multiple Myeloma
Interventions: Panobinostat, Bortezomib, Dexamethasone, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 767 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 38
States / cities: Phoenix, Arizona • Anaheim, California • Concord, California + 34 more

Conditions: Radicular; Neuropathic, Lumbar, Lumbosacral, Radicular; Neuropathic, Cervical
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Multiple Myeloma (MM)
Interventions: Cemsidomide, Elranatamab; Drug · Biological
Lead sponsor: C4 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 19
States / cities: Gilbert, Arizona • Sacramento, California • Santa Monica, California + 16 more

Conditions: Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer, CRC, RCC, ccRCC
Interventions: CB-839, Talazoparib; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more

Search by objective public record fields.

Real-Time Diagnosis of Life-Threatening Necrotizing Soft Tissue Infections (NSTI) Using Indocyanine Green (ICG) Kinetic Modeling

S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma

Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy

Investigation of the Delve Detect Cerebrospinal Fluid (CSF) Metagenomic Next-generation Sequencing (mNGS) Test When Used for the Initial Diagnostic Workup of Patients With Suspected Central Nervous System (CNS) Infection

Virtual Reality Exposure Therapy for the Treatment of Social Phobia

Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease

Linking Individuals Needing Care for Substance Use Disorders to Peer Coaches

A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia

An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

Phase 2 Efficacy Trial of Z160 in Lumbosacral Radiculopathy

PARTNERS HF: Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure

Melatonin and Ulcerative Colitis: A Pilot Clinical Trial

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

A Multisite Randomized Controlled Trial of Mindfulness Meditation Therapy for PTSD

First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age

Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

Anti-VEGF Treatment for Prevention of PDR/DME

Exercise in Patients Undergoing Urologic Surgery

Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

Comparison of Gabapentin and Pregabalin for Radicular Pain

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors